Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330179 | 0.83 | LMNA (0.40) | MEN1KMT2A | |
| SCHEMBL330541 | 0.81 | SMN1; SMN2 (0.35) | MEN1KMT2ATSHR | |
| SCHEMBL3278027 | 0.79 | MAPK1 (0.40) | MEN1KMT2ATSHR | |
| SCHEMBL329935 | 0.76 | GRM2 (0.41) | — | |
| SCHEMBL10242357 | 0.68 | ALDH1A1 (0.36) | MEN1KMT2ATSHR | |
| SCHEMBL330360 | 0.67 | ALDH1A1 (0.41) | MEN1KMT2ATSHR | |
| SCHEMBL18159481 | 0.63 | LIPA (0.41) | MEN1KMT2ATSHR | |
| SCHEMBL28455209 | 0.62 | — | — | |
| SCHEMBL21718974 | 0.58 | CHRNB2 (0.45) | MEN1KMT2A | |
| SCHEMBL21965289 | 0.56 | PKM (0.40) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | claimed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | claimed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | claimed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | claimed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | claimed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | claimed |
| EP-1649852-A1 | CHROMATOSIS REMEDIES | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-04-26 | — | — | EP | claimed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | MEN1 4484/4885KMT2A 3909/4885TSHR 4395/4885 |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | MEN1 4495/4885KMT2A 4486/4885TSHR 3741/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | MEN1 4504/4885KMT2A 4531/4885TSHR 3827/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | MEN1 4504/4885KMT2A 4531/4885TSHR 3827/4885 |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, TFEB, MAOA | MEN1 4288/4885KMT2A 1392/4885TSHR 4091/4885 |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | MEN1 4504/4885KMT2A 4531/4885TSHR 3827/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | MEN1 3254/4885KMT2A 937/4885TSHR 3558/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | MEN1 4661/4885KMT2A 4095/4885TSHR 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.